Brenetafusp

DB19441InvestigationalProtein Based Therapies

Brenetafusp is under investigation in clinical trial NCT04262466 (Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors).

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD3 and Melanoma antigen preferentially expressed in tumors
Curator reviewed
Also known as: Immunoglobulin, anti-(human CD3 antigen ε-chain) (human-Mus musculus single-chain Fv fragment VL-((GGGGS)4GGGS)-VH) fusion protein with peptide linker (GGGGS) fusion protein with T-cell receptor β chain [171-cysteine,189-alanine,203-asparatic acid] ant
Code names: IMC-F106C

Resolves to

Compound

UNII5GK14JY4JECAS2736407-54-6

Targets

P78395PRAME

What you can answer from here — as of August 05, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Brenetafusp, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account